Sunshine Biopharma Receives Third Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment
Sunshine Biopharma Inc. (OTC PINK:SBFM) announced receiving the third tranche of $800,000 from a $2,000,000 financing agreement with RB Capital Partners Inc. This funding supports the priority development of their Coronavirus treatment and clinical advancement of Adva-27a, an anticancer drug targeting pancreatic cancer. The company aims to combat SARS-CoV-2 through new molecules that inhibit viral replication. Ongoing testing and collaboration with the University of Georgia are key aspects of their development strategy.
- Secured $800,000 in funding from RB Capital Partners, supporting Coronavirus treatment and Adva-27a development.
- Ongoing collaboration with University of Georgia enhances credibility and research capabilities.
- Advancements in COVID-19 treatment with development of lead compound SBFM-PL4.
- Uncertainty in achieving profitability as highlighted in forward-looking statements.
- Significant expenses incurred in expanding service lines without guaranteed revenue.
MONTREAL, QC / ACCESSWIRE / December 1, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the third tranche of funding under the recently announced committed minimum financing of
Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, "We continue to be amazed by both the ingenuity and the work ethic of Sunshine Biopharma's leadership team. This is money well spent as every dollar is dedicated to the understanding and advancement of life-saving medicines. RB Capital is proud to invest in a company that is relentlessly working towards developing a Coronavirus treatment. The implications of such a treatment are boundless."
Sunshine Biopharma Inc. CFO, Camille Sebaaly shared, "We have a lot of important work under way, and the continued funding by RB Capital Partners enables us to keep our focus on the advancement of our oncology and antiviral drugs. We look forward to continue working with them as it is clear that they truly believe in our Company's vision."
About Sunshine Biopharma's Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/618880/Sunshine-Biopharma-Receives-Third-Tranche-From-Previously-Announced-2000000-Financing-for-Coronavirus-Treatment
FAQ
What recent funding did Sunshine Biopharma (SBFM) receive?
What is Sunshine Biopharma's focus in drug development as of December 2020?
How does Sunshine Biopharma plan to advance its Coronavirus treatment?
What is the significance of Adva-27a for Sunshine Biopharma (SBFM)?
What risks does Sunshine Biopharma (SBFM) face according to their recent press release?
